BR112022020809A2 - Composições e métodos para entrega terapêutica direcionada ao osso - Google Patents
Composições e métodos para entrega terapêutica direcionada ao ossoInfo
- Publication number
- BR112022020809A2 BR112022020809A2 BR112022020809A BR112022020809A BR112022020809A2 BR 112022020809 A2 BR112022020809 A2 BR 112022020809A2 BR 112022020809 A BR112022020809 A BR 112022020809A BR 112022020809 A BR112022020809 A BR 112022020809A BR 112022020809 A2 BR112022020809 A2 BR 112022020809A2
- Authority
- BR
- Brazil
- Prior art keywords
- bone
- compositions
- methods
- therapeutic delivery
- directed therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010639P | 2020-04-15 | 2020-04-15 | |
| PCT/US2021/027230 WO2021211683A2 (en) | 2020-04-15 | 2021-04-14 | Compositions and methods for targeted therapeutic delivery to bone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020809A2 true BR112022020809A2 (pt) | 2023-02-23 |
Family
ID=78084414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020809A BR112022020809A2 (pt) | 2020-04-15 | 2021-04-14 | Composições e métodos para entrega terapêutica direcionada ao osso |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12264187B2 (https=) |
| EP (1) | EP4135750A4 (https=) |
| JP (2) | JP2023525960A (https=) |
| KR (1) | KR102821039B1 (https=) |
| CN (1) | CN115916239A (https=) |
| AU (1) | AU2021254751B2 (https=) |
| BR (1) | BR112022020809A2 (https=) |
| CA (1) | CA3180156A1 (https=) |
| TW (1) | TW202203961A (https=) |
| WO (1) | WO2021211683A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN113166202B (zh) | 2018-10-12 | 2024-09-13 | 治疗调适公司 | 包括β-磷酸三钙-结合序列的多肽及其用途 |
| JP2023525960A (ja) | 2020-04-15 | 2023-06-20 | セラダプティブ インク | 骨に標的治療薬を送達するための組成物および方法 |
| CN121772937A (zh) * | 2023-05-30 | 2026-03-31 | 治疗调适公司 | 包含白细胞介素和钙化合物的用于治疗癌症的组合物 |
| WO2025166305A1 (en) * | 2024-02-02 | 2025-08-07 | Theradaptive, Inc. | Bone formation compositions and methods of use |
| CN120789330A (zh) * | 2025-08-04 | 2025-10-17 | 中国人民解放军总医院第四医学中心 | 一种外科钛合金融合器活性涂层的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4880610A (en) | 1988-04-20 | 1989-11-14 | Norian Corporation | In situ calcium phosphate minerals--method and composition |
| US5152791A (en) | 1989-12-07 | 1992-10-06 | Olympus Optical Co., Ltd. | Prosthetic artificial bone having ceramic layers of different porosity |
| US5491082A (en) | 1991-03-18 | 1996-02-13 | Director-General Of Agency Of Industrial Science And Technology | Plasminogen activator covalently bonded to a porous body of β-tricalcium phosphate |
| US7008634B2 (en) | 1995-03-03 | 2006-03-07 | Massachusetts Institute Of Technology | Cell growth substrates with tethered cell growth effector molecules |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| AU770196B2 (en) | 1999-02-04 | 2004-02-12 | Warsaw Orthopedic, Inc. | Osteogenic paste compositions and uses thereof |
| IL142900A0 (en) * | 1999-09-03 | 2002-04-21 | Amgen Inc | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| AU2001277854B2 (en) | 2000-06-29 | 2007-03-01 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| US20040197892A1 (en) | 2001-04-04 | 2004-10-07 | Michael Moore | Composition binding polypeptides |
| US20030113714A1 (en) | 2001-09-28 | 2003-06-19 | Belcher Angela M. | Biological control of nanoparticles |
| WO2003072593A2 (en) | 2002-02-21 | 2003-09-04 | University Of Virginia Patent Foundation | Bone targeting peptides |
| US20030221931A1 (en) | 2002-02-28 | 2003-12-04 | Steve Marsh | Sliding device |
| US20050084962A1 (en) | 2003-08-20 | 2005-04-21 | Bruce Simon | Methods of treatment using electromagnetic field stimulated stem cells |
| US7473682B2 (en) | 2003-10-29 | 2009-01-06 | Ramot At Tel Aviv University Ltd. | Angiogenic peptides and uses thereof |
| US20060051396A1 (en) | 2004-06-16 | 2006-03-09 | Affinergy, Inc. | Biofunctional coatings |
| WO2006012414A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Novel polyadenylation signal for use in expression vectors |
| US7871978B2 (en) | 2004-11-04 | 2011-01-18 | University Of Virginia Patent Foundation | Bone tropic peptides |
| WO2006062776A2 (en) | 2004-11-29 | 2006-06-15 | The Regents Of The University Of California | Hydroxyapatite-binding peptides for bone growth and inhibition |
| US20060193916A1 (en) | 2005-01-07 | 2006-08-31 | Acologix, Inc. | Formulations of peptides for periodontal and dental treatments |
| US8137664B2 (en) | 2005-02-02 | 2012-03-20 | Sdgi Holdings, Inc. | Method and kit for repairing a defect in bone |
| WO2007073661A1 (fr) * | 2005-12-26 | 2007-07-05 | Yantai Zhenghai Bio-Technology Co., Ltd. | Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee |
| US7592009B2 (en) | 2006-10-10 | 2009-09-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Polypeptide ligands for targeting cartilage and methods of use thereof |
| US9295755B2 (en) | 2006-10-18 | 2016-03-29 | Wisconsin Alumni Research Foundation | Multilayer tissue regeneration system |
| US7977313B2 (en) | 2007-04-27 | 2011-07-12 | Affinergy, Inc. | Methods and compositions for promoting localization of pharmaceutically active agents to bone |
| US8075562B2 (en) | 2007-06-25 | 2011-12-13 | Wisconsin Alumni Research Foundation | Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery |
| US20100098761A1 (en) | 2007-08-03 | 2010-04-22 | University Of Massachusetts Medical School | Polymer Compositions For Biomedical And Material Applications |
| WO2009108934A2 (en) | 2008-02-28 | 2009-09-03 | Osteotherapeutics, L.L.C. | Injectable calcium phosphate cememts formulated with bioactive agents and methods for making same |
| WO2009111014A2 (en) | 2008-03-04 | 2009-09-11 | Crystal Bioscience Inc. | Gel microdrop composition and method of using the same |
| US8158366B2 (en) | 2008-04-07 | 2012-04-17 | Auburn University | Methods of identifying peptides and compositions that bind to oocytes in a species-specific manner |
| US20100049322A1 (en) | 2008-08-19 | 2010-02-25 | Warsaw Orthopedic, Inc. | Osteochondral repair implants and methods |
| GB0818255D0 (en) * | 2008-10-06 | 2008-11-12 | Agency Science Tech & Res | Isolation and identification of glycosaminoglycans |
| CN104357381A (zh) | 2008-10-31 | 2015-02-18 | 辛西斯有限责任公司 | 用于活化干细胞的方法和装置 |
| WO2010052715A2 (en) | 2008-11-07 | 2010-05-14 | Ramot At Tel Aviv University Ltd. | Devices and methods for local treatment of cardiovascular diseases |
| US20100260673A1 (en) | 2009-04-10 | 2010-10-14 | Qizhen Cao | Phage display peptide probes for imaging early responses to antiangiogenic treatment |
| US8420774B2 (en) | 2009-12-01 | 2013-04-16 | Wisconsin Alumni Research Foundation | Decorating hydroxyapatite biomaterials with modular biologically active molecules |
| WO2011116391A1 (en) | 2010-03-19 | 2011-09-22 | Lifenet Health | Bmp-2 peptides & methods of use |
| US8778869B2 (en) | 2010-06-09 | 2014-07-15 | Wisconsin Alumni Research Foundation | Tissue regeneration system |
| EP2648740B1 (en) * | 2010-12-06 | 2022-02-09 | Massachusetts Institute of Technology | Tricalcium phosphate binding peptides and uses thereof |
| US20130268074A1 (en) | 2010-12-21 | 2013-10-10 | Prosthexis Pty Ltd | Prosthetic menisci and method of implanting in the human knee joint |
| CN102532272A (zh) | 2011-12-29 | 2012-07-04 | 陕西师范大学 | HepG2细胞表面特异性结合的多肽 |
| CN104193803B (zh) | 2014-07-25 | 2016-08-17 | 河南科技大学 | 鸭肝炎病毒i型vp1蛋白抑制肽及其应用 |
| US20160159869A1 (en) | 2014-12-09 | 2016-06-09 | Northwestern University | Bmp-2-binding peptide amphiphile nanofibers |
| CN108473981B (zh) | 2015-12-04 | 2022-04-12 | 卡里布生物科学公司 | 工程化靶向核酸的核酸 |
| EP3631450B1 (en) | 2017-05-29 | 2022-11-23 | Charité - Universitätsmedizin Berlin | Cd8 t cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery |
| US10675330B2 (en) | 2018-03-21 | 2020-06-09 | Warsaw Orthopedic, Inc. | Injectable bone morphogenetic protein |
| WO2019232283A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| CN110746500A (zh) | 2018-07-24 | 2020-02-04 | 浙江瑞谷生物科技有限公司 | 一种编码重组人骨形态发生蛋白质-2的氨基酸序列 |
| US20200102458A1 (en) | 2018-09-28 | 2020-04-02 | Icl Specialty Products Inc. | Cool Roof Coating Containing Multifunctional Additive |
| CN113166202B (zh) * | 2018-10-12 | 2024-09-13 | 治疗调适公司 | 包括β-磷酸三钙-结合序列的多肽及其用途 |
| JP7128902B2 (ja) * | 2018-12-25 | 2022-08-31 | Ｏｒｔｈｏｒｅｂｉｒｔｈ株式会社 | 複数の電界紡糸繊維からなる綿形状の構造を有する骨再生用材料 |
| US20220096600A1 (en) | 2019-02-07 | 2022-03-31 | Baylor College Of Medicine | Periosteal skeletal stem cells in bone repair |
| US20220323641A1 (en) | 2019-08-20 | 2022-10-13 | Theradaptive, Inc. | Materials for delivery of tetherable proteins in bone implants |
| US20230203115A1 (en) | 2020-03-06 | 2023-06-29 | Theradaptive, Inc. | Therapeutic compositions comprising graft materials and beta-tcp binding peptides and uses thereof |
| JP2023525960A (ja) | 2020-04-15 | 2023-06-20 | セラダプティブ インク | 骨に標的治療薬を送達するための組成物および方法 |
| AU2021297422B2 (en) | 2020-06-21 | 2023-12-14 | Orthorebirth Co., Ltd. | Osteoinductive bone regeneration material and production method of the same |
| WO2022182749A2 (en) | 2021-02-24 | 2022-09-01 | Theradaptive, Inc. | Ceramic compositions and methods of use |
-
2021
- 2021-04-14 JP JP2022562617A patent/JP2023525960A/ja active Pending
- 2021-04-14 BR BR112022020809A patent/BR112022020809A2/pt unknown
- 2021-04-14 CA CA3180156A patent/CA3180156A1/en active Pending
- 2021-04-14 AU AU2021254751A patent/AU2021254751B2/en active Active
- 2021-04-14 KR KR1020227039125A patent/KR102821039B1/ko active Active
- 2021-04-14 EP EP21787730.7A patent/EP4135750A4/en active Pending
- 2021-04-14 CN CN202180042758.XA patent/CN115916239A/zh active Pending
- 2021-04-14 WO PCT/US2021/027230 patent/WO2021211683A2/en not_active Ceased
- 2021-04-15 TW TW110113629A patent/TW202203961A/zh unknown
-
2022
- 2022-10-14 US US18/046,810 patent/US12264187B2/en active Active
-
2025
- 2025-02-20 US US19/059,012 patent/US20250179136A1/en active Pending
- 2025-09-12 JP JP2025152835A patent/JP2026004340A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021211683A2 (en) | 2021-10-21 |
| WO2021211683A3 (en) | 2021-11-18 |
| AU2021254751B2 (en) | 2025-01-30 |
| TW202203961A (zh) | 2022-02-01 |
| KR20230011289A (ko) | 2023-01-20 |
| US20250179136A1 (en) | 2025-06-05 |
| JP2026004340A (ja) | 2026-01-14 |
| EP4135750A4 (en) | 2024-08-21 |
| AU2021254751A1 (en) | 2022-11-17 |
| KR102821039B1 (ko) | 2025-06-13 |
| US20230235002A1 (en) | 2023-07-27 |
| CA3180156A1 (en) | 2021-10-21 |
| EP4135750A2 (en) | 2023-02-22 |
| CN115916239A (zh) | 2023-04-04 |
| US12264187B2 (en) | 2025-04-01 |
| JP2023525960A (ja) | 2023-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020809A2 (pt) | Composições e métodos para entrega terapêutica direcionada ao osso | |
| BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
| MX2020014296A (es) | Variantes de interleucina-2 y sus métodos de uso. | |
| BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
| AR110419A1 (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
| CU23734A1 (es) | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| CY1116511T1 (el) | Μεθοδος αγωγης του κολπικου ινιδισμου | |
| BR112014026090A2 (pt) | composição de matriz tecidual apta a fluir, estojo, método de fabricação de uma composição de matriz tecidual apta a fluir, método de tratamento, e uso da composição de matriz tecidual apta a fluir | |
| BRPI0909037B8 (pt) | compostos moduladores da atividade de tlr, e composição farmacêutica | |
| BR112023020490A2 (pt) | Composições e métodos para expressão de transgenes oculares | |
| BR112021019109A2 (pt) | Célula rpe manipulada, composições, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método para aplicar uma terapia com fvii | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas | |
| MX2021008772A (es) | Composiciones y metodos para la estimulacion de celulas natural killer. | |
| UY29639A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos | |
| CO2021000210A2 (es) | Apirasas solubilizadas, métodos y usos | |
| BR112022003633A2 (pt) | Métodos para produção de arginase 1 recombinante humana e usos da mesma | |
| CO2024007220A2 (es) | Compuestos que contienen heteroátomos y usos de estos | |
| CO2025009288A2 (es) | Productos terapéuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma | |
| CO2023001509A2 (es) | Cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias | |
| CO2020008244A2 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas | |
| BR112023004271A2 (pt) | Composições de ativação de sting polivalentes e usos das mesmas | |
| BR112018006572A2 (pt) | terapia de combinação racional para o tratamento de câncer |